Cost-utility Analysis of Rhegmatogenous Retinal Detachment Surgery in Shanghai, China

Abstract

Purpose: To perform a short-term and a long-term cost-utility analysis of rhegmatogenous retinal detachment (RRD) surgery in Shanghai, China

Methods: A total of 117 patients who underwent RRD surgery at Shanghai First People’s Hospital, Affiliated Shanghai Jiaotong University, and then underwent follow-up for at least 1 year, were included in the study. Costs associated with RRD surgery and time trade-off utility values before and after surgery were recorded. Short-term analysis was made for 1 year. Quality-adjusted life years (QALYs) gained by RRD surgery over the lifetime were calculated at a 3% discount rate in the long-term analysis. This study used the bootstrap method in statistical analysis and one-way sensitivity analyses to test robustness of the results.

Results: Compared with no treatment, the mean incremental costs of RRD surgery was 11,384 Chinese yuan (CN¥) (US$1751); the mean additional QALYs gained was 0.05 (95% confidence interval [CI] 0.04–0.06) for 1 year and 0.88 (95% CI 0.64–1.13) for life expectancy; the incremental cost effectiveness ratio (ICER) was CN¥224,921 (US$34,603)/QALY for the short-term, and CN¥13,794 (US$2122)/QALY for the long-term. In short-term analysis, the ICER was CN¥150,087 (US$23,090)/QALY for scleral buckling surgery, and CN¥507,727 (US$78,112)/QALY for vitreous surgery. In the long-term analysis, the ICER was CN¥6280 (US$966)/QALY for scleral buckling, and CN¥30,756 (US$4732)/QALY for vitreous surgery.

Conclusions: For RRD patients, surgery increases QALYs. In a 1-year analysis, surgery is not a cost-effective treatment, however it is cost-effective over the lifetime.

• Cost-utility analysis
• incremental cost-effectiveness ratio
• quality-adjusted life years
• retinal detachment
• time trade-off

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

 Funding was provided by a key grant from the Shanghai Health Bureau (20114007) and a grant from the Shanghai Leading Talent Reserve Programme (40311).